REBECCA PETTIBONE: Open Payments
NPI 1205574316 · ELMIRA, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,979 in 169 payments from 19 companies in 2025. Trend: 2023 $1,951 · 2024 $2,664 · 2025 $2,979
Food & beverage: $2,909Education: $69
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 44 | $438 |
| Madrigal Pharmaceuticals | 13 | $399 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 24 | $365 |
| ABBVIE INC. | 20 | $363 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $320 |
| Ardelyx, Inc. | 9 | $262 |
| Regeneron Healthcare Solutions, Inc. | 9 | $228 |
| Phathom Pharmaceuticals, Inc. | 14 | $167 |
| GENZYME CORPORATION | 4 | $116 |
| Exact Sciences Corporation | 3 | $75 |
Products named: TREMFYA, REZDIFFRA, XIFAXAN, DUPIXENT, IBSRELA, ENTYVIO, VOQUEZNA, LINZESS.
Industry payments across NY — which companies pay providers there.
